Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa(Wakayama Medical University), Hiroki Yamaue(Wakayama Medical University), Seiko Hirono(Wakayama Medical University), Manabu Kawai(Wakayama Medical University), Masaji Tani(Shiga University of Medical Science), Takuya Tsunoda(Tokyo University of Science), Yusuke Nakamura(Rissho University), R. Ohsawa(Wakayama Medical University)
Cited by 117
Related Papers
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy
|Nature|1998|804
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations
|Nature Genetics|2008|728
DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway
|Oncogene|2004|569
Genome-wide association study of hematological and biochemical traits in a Japanese population
|Nature Genetics|2010|535